4BB 4basebio Plc

 
TIDM4BB 
 
21 July 2021 
 
                             4basebio UK Societas 
 
                         ("4basebio" or the "Company") 
 
                             Conversion to UK PLC 
 
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of gene therapies and vaccines, 
announces that it has completed its conversion from a UK Societas to a public 
limited liability company registered in England and Wales ("PLC") 
("Conversion"). 
 
The Conversion was registered by Companies House as of 20 July 2021 and the 
Company's registration number was amended to: 13519889. 
 
The Conversion was approved by 4basebio's shareholders at the Annual General 
Meeting of the Company held on 30 June 2021. Following completion of the 
Conversion, the Company can proceed to conclude certain administrative matters 
in relation to the Conversion (including any necessary updating in relation to 
the change of name) which are expected to be completed on or around 29 July 
2021. A further announcement will be made in due course. 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                       +44 (0)12 2396 7943 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                    +44 (0)20 7213 0880 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                       +44 (0)20 7220 0500 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
Walbrook PR                                             +44 (0)20 7933 8780 or 
                                                       4basebio@walbrookpr.com 
 
Anna Dunphy / Paul McManus          Mob: +44 (0)7876 741 001 / +44 (0)7980 541 
                                                                           893 
 
 
Notes to Editors 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for gene therapies and DNA vaccines and providing solutions for effective 
and safe delivery of these DNA based products to patients. It is the intention 
of the Company to become a market leader in the manufacture and supply of high 
purity, synthetic DNA for research, therapeutic and pharmacological use. The 
immediate objectives of 4bb are to validate and scale its DNA synthesis and 
advance its collaborations to facilitate the functional validation of its DNA 
based products and gene delivery solutions. 
 
The Company divested from 4basebio AG ("4bb AG"), a German company listed on 
the Prime Standard segment of the Frankfurt Stock Exchange, following the 
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology 
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the 
disposal, 4bb AG retained its genomics business which owned and licensed 
certain intellectual property including its proprietary, patent-protected 
technology, TruePrimeT. This is the foundation for building the Company's 
synthetic DNA manufacturing business which 4bb AG transferred to the Company 
along with funding to continue the Company's development and investment. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

July 21, 2021 02:00 ET (06:00 GMT)

4basebio (LSE:4BB)
Historical Stock Chart
From Mar 2024 to Apr 2024

4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2023 to Apr 2024